Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
In summary, available data demonstrate that IL-1 and TNF are the causative agents underlying the bone loss induced by estrogen deficiency. Indeed, these factors are produced in bone and the bone marrow, released in larger amounts from cells of estrogen-deficient subjects, and indispensable for reproducing the effects of estrogen deficiency in bone. These observations support the hypothesis that the bone sparing effect of estrogen is due to the ability of the hormone to block osteoclastogenesis, the activation of mature osteoclasts and, as recently demonstrated, the rate of apoptotic osteoclast death. Although IL-1 and TNF play a prominent causal role in these events, the bone-sparing effect of estrogen is mediated by numerous cytokines which, by simultaneously stimulating multiple target cells, induce effects that are not accounted for by any one single factor (Fig. 2). The ability of estrogen to regulate some, but not all, the cytokines involved in this process is not inconsistent with this hypothesis because cytokines have potent synergistic effects. Thus, a considerable increase in bone resorption may result from a relatively small increase in the concentration of only a few of the bone-resorbing factors present in the bone microenvironment. This concept is best illustrated by the study of Miyaura et al. demonstrating that the concentrations of either IL-1, IL-6, IL-6 receptor, or prostaglandins detected in the bone marrow of OVX mice are insufficient to account for the increased bone resorption caused by estrogen withdrawal. In contrast, the increase in bone resorption induced by OVX can be explained by the cumulative effects of these cytokines. Thus, a better understanding of the cooperative effects of cytokines and a recognition that the contribution of individual cytokines to postmenopausal bone loss varies with the passage of time after menopause are necessary to fully understand the mechanism of action of estrogen in bone. Although the relevance of individual bone-targeting cytokines in species specific, the development of transgenic mice with activatable or deactivatable promoters is likely to result in a further clarification of the integrated action of estrogen-regulated cytokines in human bone cells and lay the foundations for the use of cytokine inhibitors in the treatment of postmenopausal osteoporosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Estrogen acts via suppression of bone resorption [43–45]”
From The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms (2018) · cites this paper as [44]
In the citing paper
“In addition, estrogen inhibits osteoclast formation by reducing the levels of other osteoclastogenic cytokines such as IL-1, IL-6, IL-11, TNF-α, TNF-β, and M-CSF [160, 161].”
From Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells (2015) · cites this paper as [160]
Citations
Cites
Interleukin-1 and interleukin-1 antagonism
Dinarello, C. (1991) · Blood · doi:10.1182/blood.v77.8.1627.1627 · Cited by 2,304
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6
Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B., Broxmeyer, H., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,442
Bertolini, D. R., Nedwin, G. E., Bringman, T. S., Smith, D. D., & Mundy, G. R. (1986) · Nature · doi:10.1038/319516a0 · Cited by 1,434
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040
An interleukin 1 like factor stimulates bone resorption in vitro
Gowen, M., Wood, D. D., Ihrie, E. J., McGuire, M. K. B., & Russell, R. G. G. (1983) · Nature · doi:10.1038/306378a0 · Cited by 1,012
Modulation of Osteoclast Differentiation
SUDA, T., TAKAHASHI, N., & MARTIN, T. J. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-66 · Cited by 1,004 · cited 2×
“(22) These mice, which are cured by the administration of M-CSF,(3s) have an extra thymidine inserted within the coding region of the M-CSF gene, a mutation that generates a stop codon within the coding sequence,(3h) thereby resulting in the production of a defective M-CSF.(22) The formation of osteoclasts in bone mar…”
BackgroundSoluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.
Tamura, T., Udagawa, N., Takahashi, N., Miyaura, C., Tanaka, S., Yamada, Y., Koishihara, Y., Ohsugi, Y., Kumaki, K., & Taga, T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11924 · Cited by 825
TURNER, R. T., RIGGS, B. L., & SPELSBERG, T. C. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-275 · Cited by 754
Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion.
Poli, V., Balena, R., Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., Ciliberto, G., Rodan, G. A., & Costantini, F. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06368.x · Cited by 749
Research works printed but not linked: 11
- Srivastava, 1995, Estrogen down-regulates the expression of M-CSF mRNA in bone marrow stromal cells by stimulating the production of the transcription factor EGR-1, J Bone Miner Res, 10, S18
- Matayoshi, 1995, Generation of human osteoclasts from peripheral blood cd 34+ cells, J Bone Miner Res, 10
- Pacifici, 1990, TNFα and GM-CSF secretion from human blood monocytes: Effect of menopause and estrogen replacement, J Bone Miner Res, 5, 145
- Kimble, 1996, Estrogen inhibits IL-1 and TNF gene expression in transfected murine macrophagic cells, J Bone Miner Res, 11
- Kaneki, 1991, The effect of menopause on IL-1 and IL-6 release from peripheral blood monocytes, J Bone Miner Res, 6, 76
- Thompson, 1991, IL-lra: Properties and uses of an interleukin-1 receptor antagonist, Agents Actions, 41
- Girasole, 1995, Increased serum soluble interleukin-6 receptor levels are induced by ovariectomy, prevented by estrogen replacement, and reversed by alendronate administration, J Bone Miner Res, 10, A86
- McKane, 1993, Effect of age and menopause on serum interleukin-1β and intereleukin-6- levels in women, J Bone Miner Res, 8, 162A
- Kimble, 1994, Long-term treatment with IL-1 receptor antagonist (IL-lra) blocks bone loss in ovariectomized rats, J Bone Miner Res, 9, B380
- Kimble, 1995, Inhibition of IL-6 activity is genetically normal mice does not prevent ovariectomy-induced bone loss, J Bone Miner Res, 10, s160
- Ammann, 1995, Transgenic mice expressing high levels of soluble tumor necrosis factor receptor-1 fusion protein are protected from bone loss caused by estrogen deficiency, J Bone Miner Res, 10
Cited by
Items 301–400 of 743
Advances in the research on myokine-driven regulation of bone metabolism
Shao, M., Wang, Q., Lv, Q., Zhang, Y., Gao, G., & Lu, S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22547 · Cited by 37
“Mounting evidence has shown that elevated bone resorption resulting from ovari-ectomy can be explained by the combined effects of IL-6 and other factors [74,75].”
BackgroundCrosstalk between hormones and oral health in the mid-life of women: A comprehensive review
Singh, N., Grover, C., More, V., & Grover, S. (2014) · Journal of International Society of Preventive and Community Dentistry · doi:10.4103/2231-0762.144559 · Cited by 40
“immune cells (macrophages and monocytes) and osteoclasts, which are responsible for a greater production of bone‐resorbing cytokines.[10,11] Lipopolysaccharide‐released by‐products related to periodontal tissues and bacterial plaque biofilm stimulate the production of inflammatory cytokines, which further activates th…”
BackgroundOestrogen deficiency modulates particle-induced osteolysis
Nich, C., Langlois, J., Marchadier, A., Vidal, C., Cohen-Solal, M. E., Petite, H., & Hamadouche, M. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3381 · Cited by 35
“Oestrogen deficiency also increases the RANKL/OPG ratio through increases in pro-inflammatory effectors, including IL-1b, IL-6, IL-11, TNF-a, MCSF and PGE [36].”
BackgroundRomualdo, P. C., Lucisano, M. P., Paula‐Silva, F. W. G., Leoni, G. B., Sousa‐Neto, M. D., da Silva, R. A. B., da Silva, L. A. B., & Nelson‐Filho, P. (2018) · Journal of Endodontics · doi:10.1016/j.joen.2018.01.010 · Cited by 35
Sharma, A., Hoover, D. R., Shi, Q., Tien, P. C., Weber, K. M., Shah, J., & Yin, M. T. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab874 · Cited by 38
Rossi, F., Bellini, G., Luongo, L., Mancusi, S., Torella, M., Tortora, C., Manzo, I., Guida, F., Nobili, B., de Novellis, V., et al. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.10.017 · Cited by 38
Zhang, D., Wang, Z., Qi, W., Lei, W., & Zhao, G. (2014) · Inflammation · doi:10.1007/s10753-014-9827-z · Cited by 35
“important contribution in stimulating bone resorption and suppressing bone formation [28, 29].”
BackgroundAn Increased Risk of Osteoporosis during Acquired Immunodeficiency Syndrome
Annapoorna, N., Rao, G. V., Reddy, N. S., Rambabu, P., & Rao, K. R. S. S. (2004) · International Journal of Medical Sciences · doi:10.7150/ijms.1.152 · Cited by 40
“Cytokines such as IL-1, IL-6, IL-11 and TNF-α may stimulate osteoclast activity [66-68] and enhanced IL-6 levels appear to play a pathogenic role in the enhanced bone resorption of post menopasual osteoporosis [69].”
BackgroundWennberg, P., Nordström, P., Lorentzon, R., Lerner, U. H., & Lorentzon, M. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460629 · Cited by 37
“The cytokine has been implicated in diseases with increased osteoclastic bone resorption, such as osteoporosis due to loss of gonadal function ( 12 ), rheumatoid arthritis (13), periodontitis (14), and loosening of orthopaedic implants (15).”
BackgroundKwak, D., Ha, J., Won, Y., Kwon, Y., & Park, S. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043007 · Cited by 34
Xu, J.-H., Yao, M., Ye, J., Wang, G.-D., Wang, J., Cui, X., & Mo, W. (2016) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000673 · Cited by 34
“10, 2016 primary factors in the pathogenesis of osteoporosis after menopause.(3) E plays an important role in bone formation, in the balance of E deficiency during maintenance of bone resorption and turnover.”
BackgroundLøbo, R. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00014-7 · Cited by 43
Tzagarakis-Foster, C., Geleziunas, R., Lomri, A., An, J., & Leitman, D. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205355200 · Cited by 36
Oh, K. W., Rhee, E., Lee, W., Kim, S. W., Oh, E. S., Baek, K. H., Kang, M. I., Choi, M. G., Yoo, H. J., & Park, S. W. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02090.x · Cited by 36
“Therefore, it was proposed that the major effect of oestrogen on bone tissue is the suppression of osteoclast formation and the reduction of bone resorption (Turner et al., 1994; Manolagas & Jilka, 1995; Pacifici, 1996).”
BackgroundEffects of oestrogen deficiency on osteoclastogenesis in the rat periodontium
Kawamoto, S., Ejiri, S., Nagaoka, E., & Ozawa, H. (2002) · Archives of Oral Biology · doi:10.1016/s0003-9969(01)00086-3 · Cited by 33
GIT2—A keystone in ageing and age-related disease
van Gastel, J., Boddaert, J., Jushaj, A., Premont, R. T., Luttrell, L. M., Janssens, J., Martin, B., & Maudsley, S. R. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.02.002 · Cited by 35
“RANK ligand itself is produced by osteoblasts, and binds to its receptor RANK (receptor activator of nuclear factor kappa B) on osteoclasts (Pacifici, 1996).”
BackgroundFeeding Orange Pulp Improved Bone Quality in a Rat Model of Male Osteoporosis
Morrow, R. S., Deyhim, F., Patil, B. S., & Stoecker, B. J. (2009) · Journal of Medicinal Food · doi:10.1089/jmf.2008.0145 · Cited by 33
The role of carnitine on ovariectomy and inflammation-induced osteoporosis in rats
Örsal, E., Halıcı, Z., Bayır, Y., Çadırcı, E., Bilen, H., Okkay, I. F., Aydın, A., Özkanlar, S., Ayan, A. K., Seven, B., et al. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213502614 · Cited by 34
Islam, A. A. S., Rasubala, L., Yoshikawa, H., Shiratsuchi, Y., & Ohishi, M. (2005) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2004.10.018 · Cited by 33
Morris, F. L., Payne, W. R., & Wark, J. D. (1999) · Osteoporosis International · doi:10.1007/s001980050241 · Cited by 36
“This altered bone metabolism is believed to be in response to a direct hormone action on the bone metabolic cells [28] and an indirect influence affecting the concentration and sensitivities to the bone-related factors such as the cytokines, growth hormone, insulin-like growth factor-I and the responsiveness of bone t…”
BackgroundEvolution, Aging, and Osteoporosis
Tung, S. S. Y., & Iqbal, J. Z. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.080 · Cited by 39
Saito, A., Nagaishi, K., Iba, K., Mizue, Y., Chikenji, T., Otani, M., Nakano, M., Oyama, K., Yamashita, T., & Fujimiya, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-19516-6 · Cited by 33
Arctigenin promotes bone formation involving PI3K/Akt/PPARγ signaling pathway
Li, H., Yang, C., Lan, M., Liao, X., & Tang, Z. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13659 · Cited by 31
“To date, the drugs approved for the prevention or treatment of osteoporosis show poor clinical efficacy and serious adverse reactions, including an increased risk of breast cancer using estrogen, and destructive osteonecrosis caused by the long-term use of bisphosphonate drugs (Huang et al., 2016; Pacifici, 2010).”
BackgroundDamani, J. J., Souza, M. J. D., Strock, N. C. A., Koltun, K. J., Williams, N. I., Weaver, C. M., & Rogers, C. J. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s397837 · Cited by 32
“Estrogen inhibits the production of pro-inflammatory cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-8, and IL-17, by immune cells.(21) Advancing age and hypoestrogenism after menopause trigger an upregulation of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α and promote the format…”
BackgroundResultNicot, R., Vieira, A. R., Raoul, G., Delmotte, C., Duhamel, A., Ferri, J., & Sciote, J. J. (2016) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2016.07.010 · Cited by 34
TNF-α and IL-1β Suppress N-Cadherin Expression in MC3T3-E1 Cells
Tsutsumimoto, T., Kawasaki, S., Ebara, S., & Takaoka, K. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.10.1751 · Cited by 31
“cited as a causative factor in the development of postmenopausal osteoporosis.((2)) These cytokines appear to target os-”
BackgroundMa, X., Guo, Z., Gao, W., Wang, J., Liu, Y., Gao, F., Sun, S., Zhou, X., Yang, Z., & Zheng, W. (2019) · Journal of International Medical Research · doi:10.1177/0300060519847854 · Cited by 30
“Postmenopausal osteoporosis is characterized by an increased susceptibility to fractures and decreased bone mass, which is caused by the reduced production of estrogen.(13) Estrogen prevents bone loss by regulating the secretion or release of various cytokines involved in remodeling bone structure.”
BackgroundHuang, K., Cai, S., Fu, T., Zhu, Q., Liu, L., Yao, Z., Rao, P., Lan, X., Li, Q., & Xiao, J. (2023) · Cell Proliferation · doi:10.1111/cpr.13522 · Cited by 31
“29 This leads to an increased risk of fracture, prolonged bone defect healing time, decreased formation of callus, and deteriorated biomechanical properties of new bone.”
BackgroundEffect of Estrogen on the Activity and Growth of Human Osteoclasts In Vitro
Chen, F., Wang, K.-C., & Huang, J. (2009) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/s1028-4559(09)60323-5 · Cited by 34
Huang, J. S., & Grinspoon, S. K. (2001) · The Endocrinologist · doi:10.1097/00019616-200107000-00004 · Cited by 30
Risk assessment in clinical practice
Ronderos, M., & Ryder, M. I. (2004) · Periodontology 2000 · doi:10.1046/j.0906-6713.2003.003428.x · Cited by 42
Hatori, K., Camargos, G. D. V., Chatterjee, M., Faot, F., Sasaki, K., Duyck, J. A. J., & Vandamme, K. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2857-4 · Cited by 32
“In the estrogen-deficient state, the balance between bone resorption and bone formation shifts toward an increasing level of bone resorption, which results in the loss of bone mass and deterioration of the bone micro-architecture, since that adequate estrogen level is required to inhibit osteoclast maturation at cellu…”
Background17β-Estradiol Induces Apoptosis in the Preosteoclastic FLG 29.1 Cell Line
Zecchi‐Orlandini, S., Formigli, L., Tani, A., Benvenuti, S., Fiorelli, G., Papucci, L., Capaccioli, S., Orlandini, G. E., & Brandi, M. L. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0215 · Cited by 32
Pacifici, R. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3706 · Cited by 33
“(6) confirms and extends previous reports on a possible role for cytokines in the pathogenesis of IH (4, 11).”
BackgroundSelf-citationZhao, D., Wang, Q., Zhao, Y., Zhang, H., Sha, N., Tang, D., Liu, S., Lü, S., Shi, Q., Zhang, Y., et al. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001150 · Cited by 29
Xu, Y., Yan, H., Zhang, X., Zhuo, J., Han, Y., Zhang, H., Xie, D., Lan, X., Cai, W., Wang, X., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.876269 · Cited by 33
“Postmenopausal osteoporosis (PMOP) is a systemic chronic bone metabolic disease caused by the uncoupling of bone resorption and bone formation with estrogen deficiency (1, 2).”
BackgroundFu, X., XING, L., Xu, W., & Shu, J. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5236 · Cited by 29
“1 and 2), which is often used as an experimental animal model to simulate menopause, and is associated with increased risk of bone loss (19), visceral obesity (20) and hepatic steatosis (21).”
Jang, K.-M., Cho, K.-H., Lee, S. H., Han, S.-B., Han, K., & Kim, Y. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.07.016 · Cited by 32
Li, T., Tao, Z.-S., Liu, H., Ren, M., Zhou, Z., Jiang, W.-K., & Yang, M. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-023-03695-8 · Cited by 29
“accelerates the bone remodeling cycle, severely affecting the normal bone metabolic balance [39].”
BackgroundZhao, Q., Liu, X., Zhang, L., Shen, X., Jin, Q., Wang, J., Qian, N., & Deng, L. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9739-1 · Cited by 28
“thesis of cytokines that play roles in bone formation [2, 3].”
BackgroundAbedinzade, M., Nasri, S., Omidi, M. J., Ghasemi, E., & Ghorbani, A. (2015) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.26685 · Cited by 31
“Menopause is also associated with a wide range of changes in the expression and secretion of proinflammatory cytokines which may explain increased incidence of osteoporosis, Alzheimer, arthritis, and other inflammatory diseases seen in a postmenopausal period (6-9).”
BackgroundIwamoto, J., Takeda, T., & Satō, Y. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.16.2743 · Cited by 29
RetractedIncreased Bone Resorbing Activity of Peripheral Monocyte Culture Supernatants in Elderly Women
Cohen-Solal, M. E., Boitte, F., Bernard-Poenaru, O., Denne, M. A., Graulet, A. M., Brazier, M., & de Vernejoul, M. C. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.5.4808 · Cited by 29
“As suggested earlier, IL-1 is one of the underlying factors promoting bone resorption in situations of early estrogen deficiency ( 4 ).”
BackgroundLucateli, R. L., Silva, P. H. F., Salvador, S. L. D. S., Ervolino, E., Furlaneto, F. A. C., Marciano, M. A., Antunes, T. B. M., Arco, M. C. G. D., Tardelli, M. D. C., de Sousa, L. G., et al. (2024) · Journal of Periodontal Research · doi:10.1111/jre.13256 · Cited by 29
Optimising the management of osteoporosis
Farah, Z., & Jawad, A. S. (2020) · Clinical Medicine · doi:10.7861/clinmed.2020-0131 · Cited by 31
Zhou, M.-S., & Tao, Z.-S. (2022) · Bone and Joint Research · doi:10.1302/2046-3758.1111.bjr-2022-0017.r2 · Cited by 28
The protective effect of lycopene intake on bone loss in ovariectomized rats
IIMURA, Y., Agata, U., Takeda, S., Kobayashi, Y., Yoshida, S., Ezawa, I., & Omi, N. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0596-4 · Cited by 27
Association between liver enzymes and bone mineral density in Koreans: a cross-sectional study
Do, H. J., Shin, J., Lee, J., Lee, Y. J., Kim, M.-R., Nam, D., Kim, E., Park, Y., Suhr, K., & Ha, I. (2018) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-018-2322-1 · Cited by 28
Tantikanlayaporn, D., Wichit, P., Suksen, K., Suksamrarn, A., & Piyachaturawat, P. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110763 · Cited by 28
Association of gene variants in TLR4 and IL-6 genes with Perthes disease
Dražilov, S. S., Spasovski, V., Spasovski, D., Živković, Z., Matanović, D., Baščarević, Z., Terzić-Šupić, Z., Stojiljković, M., Karan-Djurašević, T., Stanković, B., et al. (2014) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh1408450s · Cited by 30
Pasteurella multocidaToxin-Stimulated Osteoclast Differentiation Is B Cell Dependent
Hildebrand, D., Heeg, K. M., & Kubatzky, K. F. (2010) · Infection and Immunity · doi:10.1128/iai.00565-10 · Cited by 30
Veldhuis, J. D., Evans, W. S., Bowers, C. Y., & Anderson, S. M. (2001) · Endocrine · doi:10.1385/endo:14:1:045 · Cited by 30
Li, R., Ruan, Q., Yin, F., & Zhao, K. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.11.004 · Cited by 27
Liu, Y., Zhou, Y. G., Zhang, L., Li, J., Tian, Q., Zhang, J., & Deng, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116792 · Cited by 27
“They are osteoclast progenitor cells [7–10] and produce cytokines for osteoclastogenesis and bone resorption [11,12].”
BackgroundSchulze, J., Riecken, K., Baranowsky, A., Streichert, T., Lange, T., Spiro, A. S., Albers, J., Seitz, S. A., Zustin, J., Amling, M., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.11.016 · Cited by 29
Wang, Q., Zhao, Y., Sha, N., Zhang, Y., Li, C., Zhang, H., Tang, D., Lü, S., Shi, Q. W., Wang, Y., et al. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.01.007 · Cited by 27
Dietary Retinol—A Double-edged Sword
Denke, M. A. (2002) · JAMA · doi:10.1001/jama.287.1.102 · Cited by 26
Wang, Z., Wu, J., Li, L., Wang, K., Wu, X., Chen, H., Shi, J., Zhou, C., Zhang, W., Hang, K., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.07.022 · Cited by 26
Tani, A., Yasui, T., Matsui, S., Kato, T., Kunimi, K., Tsuchiya, N., Yuzurihara, M., Kase, Y., & Irahara, M. (2013) · Cytokine · doi:10.1016/j.cyto.2013.02.011 · Cited by 25
Gonçalves, V. D. P., Ortega, A., Steffens, J. P., Spolidório, D. M. P., Rossa, C., & Spolidório, L. C. (2018) · Journal of Periodontology · doi:10.1002/jper.17-0457 · Cited by 25
IL‐1α and IL‐1β have different effects on formation and activity of large osteoclasts
Trebec‐Reynolds, D. P., Voronov, I., Heersche, J. N. M., & Manolson, M. F. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22476 · Cited by 30
“Increased levels of IL-1b have been reported in cases of osteoporosis and rheumatoid arthritis [Eastgate et al., 1988; Pacifici, 1996], and the effects of IL-1a and IL-1b on OCs have been tested in vitro.”
BackgroundEstrogen inhibits Dlk1/FA1 production: A potential mechanism for estrogen effects on bone turnover
Abdallah, B. M., Bay‐Jensen, A., Srinivasan, B., Tabassi, N. C.-B., Garnero, P., Delaissé, J., Khosla, S., & Kassem, M. S. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.444 · Cited by 25
“Estrogen deficiency leads to increased bone turnover and increased osteoclastic bone resorption owing to enhanced production of a number of proinflammatory and osteoclastogenic cytokines.((2)) Delta-like 1/preadipocyte factor 1 (Dlk1/Pref1) is an imprinted gene encoding a transmembrane protein that belongs to the epid…”
BackgroundWang, T., Liu, Q., Zhou, L., Yuan, J., Lin, X., Zeng, R., Liang, X., Zhao, J., & Xu, J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161126039 · Cited by 27
“Estrogen suppresses osteoclast formation by inhibiting osteoclastogenic cytokines such as IL-1, IL-6, IL-11, and TNF-α [37,38].”
BackgroundThe Effects of Menopause on Periodontal Tissue
Yıldırım, T. T., & Kaya, F. A. (2011) · International Dental Research · doi:10.5577/intdentres.2011.vol1.no3.2 · Cited by 28
Sex differences in systemic bone and muscle loss following femur fracture in mice
Osipov, B., Paralkar, M. P., Emami, A. J., Cunningham, H. C., Tjandra, P. M., Pathak, S. J., Langer, H. T., Baar, K., & Christiansen, B. (2021) · Journal of Orthopaedic Research® · doi:10.1002/jor.25116 · Cited by 28
“males may contribute to greater osteoclast activation or impairment in osteoblast function at distant skeletal sites in males.(19) On the other hand, IL‐6 and IL‐1β concentrations did not differ between male and female fracture mice, and concentrations of IL‐10, an anti‐inflammatory cytokine that protects against bone…”
BackgroundShaughnessy, S. G., Walton, K. J., Deschamps, P. A., Butcher, M. K., & Beaudin, S. M. (2002) · Cytokine · doi:10.1006/cyto.2002.1981 · Cited by 24
Webster, R. P., Sheriff, S., Faroqui, R., Siddiqui, F., Hawse, J. R., & Amlal, H. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00542.2015 · Cited by 25
“In fact, it is well established that estrogen depletion in postmenopausal women is associated with bone fragility and osteoporosis (19, 30, 41, 53).”
BackgroundIs GSN significant for hip BMD in female Caucasians?
Deng, F., Zhu, W., Zeng, Y., Zhang, J., Yu, N., Liu, Y., Liu, Y.-J., Tian, Q., & Deng, H. (2014) · Bone · doi:10.1016/j.bone.2014.02.015 · Cited by 23
Medeiros, A. R. S., Lamas, A. Z., Caliman, I. F., Dalpiaz, P. L. M., Firmes, L. B., Abreu, G. R., Moysés, M. R., Lemos, E. M., dos Reis, A. M., & Bissoli, N. S. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.08.015 · Cited by 23
Lin, C., Lin, C., Liu, C.-S., Yang, C., Lin, C., Hsiao, J.-H., Meng, N., Lin, C., Liao, L.-N., Li, C.-I., et al. (2016) · Molecular Biology Reports · doi:10.1007/s11033-016-4037-4 · Cited by 23
Role of parathyroid hormone in mediating age-related changes in bone resorption in men
Kennel, K. A., Riggs, B. L., Achenbach, S. J., Oberg, A. L., & Khosla, S. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1417-0 · Cited by 24
“Estrogen probably acts at multiple levels: it directly reduces bone resorption [23], blocks the pro-resorptive effects of PTH (21), and over the long term, improves calcium balance through effects on intestinal [6] and renal calcium handling [7, 8], resulting in an amelioration of the secondary hyperparathyroidism in…”
BackgroundYang, T., Guo, Y., Zhang, J., Xu, C., Tian, Q., & Deng, H. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2558 · Cited by 22
“Monocytes are important for osteoporosis by serving as osteoclast progenitor cells((38,39)) and producing cytokines for osteoclastogenesis and bone resorption.((40)) Among these genes affected by ROHs, somemay have potential connection with bone or osteoporosis.”
BackgroundThe role of estrogens in osteosarcopenia: from biology to potential dual therapeutic effects
Mandelli, A., Tacconi, E., Levinger, I., Duque, G., & Hayes, A. (2021) · Climacteric · doi:10.1080/13697137.2021.1965118 · Cited by 23
Liu, Z., Liu, L., Chen, K., Xie, Q., Zhang, B., & Li, Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3891 · Cited by 22
Seitz, S. A., Keller, J., Schilling, A. F., Jeschke, A., Marshall, R. P., Stride, B. D., Wintermantel, T. M., Beil, F. T., Amling, M., Schütz, G., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050301 · Cited by 25
Rahman, M. M., Fernandes, G., & Williams, P. (2013) · Lipids · doi:10.1007/s11745-013-3872-5 · Cited by 22
“Estrogen prevents bone loss through a complex set of mechanisms that ultimately reduce osteoclast formation and enhance their apoptosis, thereby reducing the ability of these cells to resorb bone [47, 49–53].”
BackgroundGe, G., Yang, S., Hou, Z., Gan, M., Tao, H., Zhang, W., Li, W., Wang, Z., Hao, Y., Gu, Y., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648969 · Cited by 22
“The decrease of estrogen promotes the release of proinflammatory cytokines including interleukin-1 (IL1), IL-6 and tumor necrosis factor α (TNF-α), which hinders the activation of osteoblasts and reduces bone formation (Pacifici, 1996).”
BackgroundTsuji, S., Munkhbat, B., Hagihara, M., Tsuritani, I., Abe, H., & Tsuji, K. (1998) · Human Immunology · doi:10.1016/s0198-8859(98)00009-3 · Cited by 22
Short-Range Intercellular Calcium Signaling in Bone
Jørgensen, N. R. (2005) · Apmis · doi:10.1111/j.0903-465x.2005.apm_vol113_suppl118.x · Cited by 23
Chenopodium ambrosioides L. extract prevents bone loss
Soares, C. D., de Carvalho, M. G. F., de Carvalho, R. A., Trindade, S. R. P., do Rêgo, A. C. M., Araújo-Filho, I., & Marques, M. M. (2015) · Acta Cirúrgica Brasileira · doi:10.1590/s0102-865020150120000004 · Cited by 52
Impaired Estrogen Sensitivity in Bone by Inhibiting Both Estrogen Receptor α and β Pathways
Ogawa, S., Fujita, M., Ishii, Y., Tsurukami, H., Hirabayashi, M., Ikeda, K., Orimo, A., Hosoi, T., Ueda, M., Nakamura, T., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909675199 · Cited by 24
Orosomucoid: a mortality risk factor in elderly people living in the community?
Raynaud-Simon, A., Lafont, S., Berr, C., Dartigues, J., & Bouc, Y. L. (2002) · Clinical Nutrition · doi:10.1054/clnu.2002.0534 · Cited by 24
Camargos, G. D. V., Bhattacharya, P., van Lenthe, H., Cury, A. A. D. B., Naert, I. E., Duyck, J. A. J., & Vandamme, K. (2015) · Scientific Reports · doi:10.1038/srep10795 · Cited by 22
Zhu, M., Xu, W., Jiang, J., Wang, Y., Guo, Y., Yang, R., Chang, Y., Zhao, B., Wang, Z., Zhang, J., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.736863 · Cited by 22
“Estrogen has the ability to block osteoclastogenesis and increase OC apoptosis, and the withdrawal of estrogen increases the number of OCs and promotes bone resorption (47).”
BackgroundShi, X., Jiang, J., Ru, H., Xu, F., & Dai, S. (2023) · Mediators of Inflammation · doi:10.1155/2023/2613766 · Cited by 21
“A study involving 45 postmenopausal women showed that the circulating levels of IL-1β, IL-6, and TNF-α in postmenopausal women with osteoporosis were significantly higher than those without osteoporosis.”
BackgroundHarding, G., Mak, Y. T., Evans, B. A. J., Cheung, J., MacDonald, D., & Hampson, G. (2006) · Cytokine · doi:10.1016/j.cyto.2006.10.012 · Cited by 23
Dündar, Ü., Kavuncu, V., Çiftçi, İ. H., Evcik, D., Solak, Ö., & Çakır, T. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0055-9 · Cited by 23
“These cytokines increase bone resorption mainly by increasing the pool size of preosteoclasts in bone marrow [2, 4, 7, 8].”
BackgroundEvaluation and treatment of postmenopausal osteoporosis.
Wang, C. Y., Bruder, J., & Rubin, C. D. (2001) · PubMed · Cited by 21
Yasui, T., Uemura, H., Yamada, M., Matsuzaki, T., Tsuchiya, N., Noguchi, M., Yuzurihara, M., Kase, Y., & Irahara, M. (2008) · Cytokine · doi:10.1016/j.cyto.2007.12.001 · Cited by 22
Santos, P. C. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.6.2018.tde-11042018-150743 · Cited by 22
Kim, Y.-Y., Kim, S., Oh, S.-R., Sul, O., Lee, H., Kim, H., Kim, S., & Choi, H. (2010) · Molecules and Cells · doi:10.1007/s10059-010-0027-x · Cited by 21
“Upregulation of OC formation is primarily responsible for bone loss induced by estrogen deficiency ( Pacifici, 1996 ).”
BackgroundLisco, G., Triggiani, D., Giagulli, V. A., Pergola, G. D., Guastamacchia, E., Piazzolla, G., Jirillo, E., & Triggiani, V. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230330121301 · Cited by 21
Salimi, M., Khanzadeh, M., Nabipoorashrafi, S. A., Seyedi, S. A., Yaghoobpoor, S., Brismée, J., Lucke-Wold, B. P., Ebadi, M., Ghaedi, A., Singh, V. K., et al. (2024) · BMC Women s Health · doi:10.1186/s12905-024-03006-1 · Cited by 20
“Estrogen interacts with a variety of immune cells, resulting in a chronic low degree pro-inflammatory condition for estrogen-deficient individuals [28–30].”
BackgroundCyclopia Extracts Act as ERα Antagonists and ERβ Agonists, In Vitro and In Vivo
Visser, K., Mortimer, M., & Louw, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079223 · Cited by 28
“The decline in estrogen levels during menopause leads to a surge in the occurrence of inflammatory disorders [52,90-92].”
BackgroundTella, S. H., & Gallagher, J. C. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.844790 · Cited by 23
“The important action of estrogen is to increase OPG secretion [3] and decrease M-CSF [1] and RANK [4].”
BackgroundInfluentialIdentification of candidate genes in osteoporosis by integrated microarray analysis
Li, J. J., Wang, B. Q., Fei, Q., Yang, Y., & Li, D. (2016) · Bone and Joint Research · doi:10.1302/2046-3758.512.bjr-2016-0073.r1 · Cited by 21
Xiao, K.-W., Li, J.-L., Zeng, Z., Liu, Z., Hou, Z., Yan, X., & Cai, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-53843-6 · Cited by 22
Osteoporosis: Pathogenesis, Diagnosis, and Treatment in Older Adults
Prestwood, K. M., & Kenny, R. A. (1998) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(18)30106-x · Cited by 24
Osteocytes in the pathogenesis of osteoporosis
Ikeda, K. (2008) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2008.00481.x · Cited by 22
Méndez‐Dávila, C., García-Moreno, C., Turbí, C., & de la Piedra, C. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03347531 · Cited by 20
Metadata
- Authors
- Pacifici, R.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Pacifici, Roberto
- ORCID
- Pacifici, Roberto
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-08-01
- Volume
- 11
- Issue
- 8
- Pages
- 1043-1051
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2110993073
- Cited by
- 741
- References
- 90
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 15 · 2023: 20 · 2022: 20 · 2021: 24 · 2020: 20 · 2019: 26 · 2018: 30 · 2017: 15 · 2016: 19 · 2015: 31 · 2014: 29 · 2013: 22 · 2012: 28
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ag013534-04)
- National Institute on Aging (AG 13534)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR041412, AR41412)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- postmenopausal osteoporosis, estrogen deficiency, cytokines, interleukin-1, TNF-α, bone resorption, osteoclastogenesis, osteoclast apoptosis, bone marrow, cytokine synergy, estrogen withdrawal, cytokine inhibitors
- MeSH terms
- Animals, Bone and Bones, Bone Resorption, Estrogens, Female, Humans, Menopause, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Cytokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.